Table 1

Patient characteristics

Characteristics

N = 20


Epidemiology

Age, y, mean ± SD

31 ± 8

Female gender, n (%)

20 (100)

Previous SLE manifestations

Skin, n (%)

11 (55)

Joints, n (%)

9 (45)

Serositis, n (%)

4 (20)

Kidney, n (%)

11 (55)

Central nervous system, n (%)

1 (5)

SELENA-SLEDAI at Day 0, mean (range)

2 (0 to 8)

25-Hydroxyvitamin D levels

Mean ± SD, ng/mL

22 ± 11

25(OH)D ≤ 10 ng/mL, n (%)

1 (5)

11 < 25(OH)D ≤ 20 ng/mL, n (%)

11 (55)

21 < 25(OH)D ≤ 30 ng/mL, n (%)

8 (40)

Associated treatments*

Prednisone, n (%)

14 (70)

Prednisone, median, mg/day (range)

5 (0 to 15)

Hydroxychloroquine, n (%)

17 (85)

Azathioprine, n (%)

2 (10)

Mycophenolate mofetil, n (%)

1 (5)


*At the time of the study. SLE: systemic lupus erythematosus; SELENA-SLEDAI: Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; 25(OH)D: 25-hydroxyvitamin D.

Terrier et al. Arthritis Research & Therapy 2012 14:R221   doi:10.1186/ar4060

Open Data